Total Funding
74
20
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
89753
Modus Therapeutics is a Swedish drug development company focused on normalizing the lives for patients with Sickle Cell Disease.
- Ellen Donnelly: CEOPast Role: Abliva AB, Chief Executive Officer
- Mats Wahlgren: Co-Founder, Chief Scientific Officer
About the Company
Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
